In addition to STAMP2 effects on PCa growth and survival, and its correlation with tumor grade and response to hormone therapy (Figs1 and 4), STAMP2 targeting by systemic administration of nanoliposome-encapsulated siRNA resulted in profound tumor regression in two independent preclinical models of human PCa (Fig10A and B). This evidence concerns the gene STEAP4 and neoplasm.